Results 31 to 40 of about 21,795 (202)

Domino living donor liver transplantation of familial amyloid polyneuropathy patient - A case report - [PDF]

Anesthesia and Pain Medicine, 2020
Background Familial amyloid polyneuropathy (FAP) is caused by mutation in a gene transcribing transport protein produced mainly by the liver. Liver transplantation is required to stop FAP progression, but the pathology causes anesthetic management ...
Sungrok Cha, Jiwon Kim, Soo Joo Choi, Gaab Soo Kim   +3 more
doaj   +1 more source

Accurate, strong, and stable reporting of choroid plexus epithelial cells in transgenic mice using a human transthyretin BAC

Fluids and Barriers of the CNS, 2018
Background Choroid plexus epithelial cells express high levels of transthyretin, produce cerebrospinal fluid and many of its proteins, and make up the blood-cerebrospinal fluid barrier. Choroid plexus epithelial cells are vital to brain health and may be
Brett A. Johnson, Margaret Coutts, Hillary M. Vo, Xinya Hao, Nida Fatima, Maria J. Rivera, Robert J. Sims, Michael J. Neel, Young-Jin Kang, Edwin S. Monuki   +9 more
doaj   +1 more source

Structure-Based Probe Reveals the Presence of Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients

JACC: Basic to Translational Science
Summary: Amyloidogenic transthyretin (ATTR) amyloidosis is a relentlessly progressive disease caused by the misfolding and systemic accumulation of amyloidogenic transthyretin into amyloid fibrils.
Rose Pedretti, BS, Lanie Wang, BS, Anna Yakubovska, MS, Qiongfang S. Zhang, BS, Binh Nguyen, PhD, Justin L. Grodin, MD, Ahmad Masri, MD, Lorena Saelices, PhD   +7 more
doaj   +1 more source

Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy

Journal of the American College of Cardiology, 2019
Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging. Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions. AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that ...
Daniel P, Judge, Stephen B, Heitner, Rodney H, Falk, Mathew S, Maurer, Sanjiv J, Shah, Ronald M, Witteles, Martha, Grogan, Van N, Selby, Daniel, Jacoby, Mazen, Hanna, Jose, Nativi-Nicolau, Jignesh, Patel, Satish, Rao, Uma, Sinha, Cameron W, Turtle, Jonathan C, Fox   +15 more
openaire   +2 more sources

Stroke volume and myocardial contraction fraction in transthyretin amyloidosis cardiomyopathy: A systematic review

Frontiers in Cardiovascular Medicine, 2023
BackgroundCardiac amyloidosis (CA) is primarily a restrictive cardiomyopathy in which the impairment of diastolic function is dominant. Despite this, the left ventricular ejection fraction (LVEF) may be depressed in the late stage of the disease, but it ...
Serenelli Matteo, Cantone Anna, Sanguettoli Federico, Maio Daniele, Fabbri Gioele, Dal Passo Beatrice, Pavasini Rita, Tonet Elisabetta, Passarini Giulia, Rapezzi Claudio, Campo Gianluca   +10 more
doaj   +1 more source

Functional and Structural Evidence of Neurofluid Circuit Aberrations in Huntington Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Disrupted neurofluid regulation may contribute to neurodegeneration in Huntington disease (HD). Because neurofluid pathways influence waste clearance, inflammation, and the distribution of central nervous system (CNS)–delivered therapeutics, understanding their dysfunction is increasingly important as targeted treatments emerge.
Kilian Hett, Abigail Dubois, Melanie Leguizamon, Alexander Song, Paula Trujillo, Colin D. McKnight, Ciaran M. Considine, Manus J. Donahue, Daniel O. Claassen   +8 more
wiley   +1 more source

Determinants of transthyretin levels and their association with adverse clinical outcomes among UK Biobank participants

Nature Communications
Transthyretin is a transport protein whose misfolding has been implicated in the development of cardiac amyloidosis. Here, we examine the clinical correlates of transthyretin levels, the differences in transthyretin levels according to the pathogenic ...
Naman S. Shetty, Mokshad Gaonkar, Nirav Patel, Akhil Pampana, Nehal Vekariya, Peng Li, Garima Arora, Pankaj Arora   +7 more
doaj   +1 more source

Transthyretin (TTR) Cardiac Amyloidosis [PDF]

Circulation, 2012
(Uploaded by Plazi for the Bat Literature Project) No abstract provided.
Frederick L, Ruberg, John L, Berk
openaire   +2 more sources

From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function

Advanced Healthcare Materials, EarlyView.
The evolution of lipid nanoparticles (LNPs) spans from RNA‐LNPs, used in mRNA vaccines, to DNA‐LNPs, ideal for gene therapies. Emerging bionano architectures, decorated with DNA and plasma proteins, pave the way for advanced DNA‐based therapies that are more stable, targeted, and customizable.
Erica Quagliarini, Daniela Pozzi, Giulio Caracciolo   +2 more
wiley   +1 more source

Early Progression of Aortic Stenosis Associated With Iatrogenic Variant Transthyretin Amyloidosis After Domino Liver Transplantation

JACC: Case Reports, 2020
We report a 65-year-old man who underwent aortic valve replacement because of severe aortic stenosis associated with de novo iatrogenic variant transthyretin amyloidosis derived from a liver graft extracted from a patient with hereditary transthyretin ...
Yasuhito Hosoda, MD, Mitsuharu Ueda, MD, PhD, Jun Takaki, MD, Ken Okamoto, MD, PhD, Taro Yamashita, MD, PhD, Toshihiro Fukui, MD, PhD   +5 more
doaj   +1 more source